According to the report, the global clinical trials market was valued over US$ 46.7 Bn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030.
Clinical trials Market: Introduction
According to the report, the global clinical trials market was valued over US$ 46.7 Bn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. High prevalence and increase in incidence rate of chronic diseases, and rise in R&D activities in biotechnology & pharmaceuticals industries are anticipated to drive the global clinical trials market from 2020 to 2030. North America is projected to be a highly attractive market during the forecast period. The region is anticipated to account for the largest share of the global market by 2030. The market in the region is expected to grow at a rapid pace from 2020 to 2030. Increase in R&D and rise in adoption of new technologies in clinical research are likely to propel the market in North America. The incorporation of virtual services in the clinical trial protocol by market players such as IQVIA and PRA Health Sciences is projected to boost the market in North America.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78053
Europe is anticipated to be the second most attractive market for clinical trials during the forecast period. Support from the government for activities such as research & development for new treatment procedures and upcoming infectious diseases, along with chronic diseases are expected to drive the clinical trials market in Europe during the forecast period.
The market in Asia Pacific is expected to expand at the highest CAGR from 2020 to 2030. Increase in the number of clinical trials and biotechnology firms in Asia Pacific is projected to drive the clinical trials market in the region over the next few years.
Request for Analysis of COVID-19 Impact on Clinical Trials Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78053
High Prevalence and Increase in Incidence Rate of Chronic Diseases to Drive Market
Chronic diseases such as chronic respiratory diseases (CRD), diabetes, chronic kidney diseases (CKD), cancer, cardiac stroke, and neurological disorders are the leading causes of disability and mortality across the globe. The emergence and outbreak of various infectious and chronic diseases have created challenges and new opportunities for researchers to develop new diagnostic tools, tests, drugs, and vaccines for early diagnosis, prevention, and cure of such diseases. Hepatitis and HIV are the other major infectious diseases. According to the World Health Organization (WHO), as of October 2017, around 71 million people across the world were estimated to have hepatitis C infection. The WHO also stated that 36.7 million people were affected with HIV across the globe. These factors contribute to the growth of the global clinical trials market.
Buy Clinical Trials Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=78053<ype=S
Rise in R&D Activities in Biotechnology and Pharmaceuticals Industries Propels Global Market
Clinical research organizations, diagnostic laboratories, and biotechnology players are engaged in the development of newer diagnostic tests to address the unmet needs in the healthcare industry. The life science industry’s R&D spending is driven primarily by the mass and research intensity of the biopharmaceutical sector, which accounts for nearly 85% of all expenditures. The acceleration in biopharmaceutical R&D innovation, buoyed by several contributing factors such as precision medicine getting into gear in rare diseases, cancer, and autoimmune diseases; immunotherapy, expansion of therapeutic modalities exploiting natural and synthetic biology innovation, and expedited regulatory pathways boost the growth of the clinical trials market.
Phase III to Dominate Market
In terms of phase, the global clinical trials market has been divided into phase I, phase II, phase III, and phase IV. The phase III segment held major market share in 2019 and the trend is projected to continue during the forecast period. The segment is anticipated to register the highest market attractiveness during the forecast period.
Top of Form
Ask for Discount :
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=78053
Oncology to be Major Indication
Based on indication, the global clinical trials market has been classified into autoimmune/inflammation, pain management, cardiovascular, CNS condition, oncology, diabetes, obesity, and others. The oncology segment accounted for major share of 23.5% of the global clinical trials market in 2019. The oncology segment is anticipated to create incremental opportunity of US$ 8,758.5 Mn during the forecast period. The segment is projected to capture 24.4% market share by 2030. The segment is expected to expand at a high CAGR of 5.8% from 2020 to 2030. The growth of the segment can be attributed to increase in the number of clinical trials in the oncology segment.
Competition Landscape in Clinical Trials Market
The report provides profiles of leading players operating in the global clinical trials market. These include Laboratory Corporation of America Holdings, IQVIA, Inc., Syneos Health, Parexel International Corporation, PRA Health Sciences, Inc., PPD, Inc., Icon plc, Charles River Laboratories, Inc., WuXi AppTec, and Medpace Holdings, Inc.
Browse more Market Reports:
Diagnostic Imaging Services Market:
Imaging service plays crucial role in medical field. It is used for prompt diagnosis of any medical condition, monitoring medical condition at the time of treatment, and also as a part of preventive measures. Rising awareness among consumers regarding early detection of disease is providing lucrative growth opportunities.
With the increasing growth of the healthcare industry, healthcare organizations and professionals have shifted to value-based business models. Improving surgical outcome is taking center stage in new experience-driven business models of the industry, and postoperative care has attracted the attention of healthcare professionals.
Structural Heart Devices Market:
Structural heart devices technology has seen a paradigm shift with the advent of non-invasive procedures to treat aortic stenosis and mitral regurgitation. From a previously sluggish approach, there seems to be a spate of activity characterized by investor excitement and massive research & development (R&D) initiatives regarding minimally-invasive heart valve technologies. For cardio-thoracic surgeons and interventional cardiologists, this arena offers tremendous scope and potential vis-à-vis traditional open heart surgery that is associated with severe side-effects.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453